Beclometason / formoterol / glycopyrroniumbromide Medicine 04 June 2026 Extended indication Extension of indication to include treatment of asthma. Therapeutic value Total cost Registration phase Registration application pending Product Active substance Beclometason / formoterol / glycopyrroniumbromide Domain Lung diseases Reason of inclusion Indication extension IND Main indication Asthma Extended indication Extension of indication to include treatment of asthma. Current proprietary name Already available biosimilars / generics Proprietary name Trimbow Manufacturer Chiesi Portfolio holder Chiesi Mechanism of action Route of administration Inhalation Therapeutical formulation Inhalation powder Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date December 2025 Expected Registration July 2026 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration 2 times a day Dosage per administration 88 + 5 + 9 micrograms (2 inhalations) References NCT02676076 (TRIMARAN) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost € 600.00 - 700.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Additional remarks 88 + 5 + 9 microgram metered dose inhaler (360 dose package size) €159.90. Als de patiënt in een jaar twee inhalers gebruikt zullen de kosten ongeveer €650 per patiënt zijn. Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks